JP2021525783A5 - - Google Patents
Info
- Publication number
- JP2021525783A5 JP2021525783A5 JP2020568258A JP2020568258A JP2021525783A5 JP 2021525783 A5 JP2021525783 A5 JP 2021525783A5 JP 2020568258 A JP2020568258 A JP 2020568258A JP 2020568258 A JP2020568258 A JP 2020568258A JP 2021525783 A5 JP2021525783 A5 JP 2021525783A5
- Authority
- JP
- Japan
- Prior art keywords
- hydroxymethyl
- benzyl
- pyridine
- pyrazine
- fluoro
- Prior art date
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/090385 | 2018-06-08 | ||
| CN2018090385 | 2018-06-08 | ||
| CN2018120975 | 2018-12-13 | ||
| CNPCT/CN2018/120975 | 2018-12-13 | ||
| PCT/CN2019/090221 WO2019233457A1 (zh) | 2018-06-08 | 2019-06-06 | Erk抑制剂及其应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021525783A JP2021525783A (ja) | 2021-09-27 |
| JPWO2019233457A5 JPWO2019233457A5 (https=) | 2022-05-16 |
| JP2021525783A5 true JP2021525783A5 (https=) | 2022-05-16 |
Family
ID=68770778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568258A Pending JP2021525783A (ja) | 2018-06-08 | 2019-06-06 | Ｅｒｋ阻害剤及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11466013B2 (https=) |
| EP (1) | EP3805217A4 (https=) |
| JP (1) | JP2021525783A (https=) |
| KR (1) | KR20210018915A (https=) |
| CN (1) | CN112204024B (https=) |
| AU (1) | AU2019280356B2 (https=) |
| CA (1) | CA3103055A1 (https=) |
| IL (1) | IL279276A (https=) |
| SG (1) | SG11202012241RA (https=) |
| TW (1) | TW202016102A (https=) |
| WO (1) | WO2019233457A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021110169A1 (zh) * | 2019-12-06 | 2021-06-10 | 南京明德新药研发有限公司 | 作为erk抑制剂的噻唑并内酰胺类化合物及其应用 |
| WO2022253186A1 (zh) * | 2021-06-02 | 2022-12-08 | 南京明德新药研发有限公司 | 一种二甲基取代的噻唑并吡咯酮类化合物的晶型及其制备方法 |
| WO2022268065A1 (en) * | 2021-06-22 | 2022-12-29 | Fochon Biosciences, Ltd. | Compounds as erk inhibitors |
| US20240270743A1 (en) * | 2021-08-11 | 2024-08-15 | Landos Biopharma, Inc. | Tetrahydropyrazolopyridine-analog ligands of nlrx1 and uses thereof |
| WO2024218632A1 (en) * | 2023-04-17 | 2024-10-24 | Array Biopharma Inc. | Erk protein kinase inhibitors |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| CN117209485A (zh) * | 2023-08-31 | 2023-12-12 | 四川大学华西医院 | 一种具有抗肿瘤活性的嘧啶骨架类化合物及其制备方法和应用 |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0202332A2 (en) * | 2000-02-05 | 2002-10-28 | Vertex Pharma | Pyrazole compositions useful as inhibitors of erk |
| GB0614070D0 (en) * | 2006-07-14 | 2006-08-23 | Glaxo Group Ltd | Compounds |
| JP2011511756A (ja) * | 2007-08-02 | 2011-04-14 | ナームローゼ・フエンノートチヤツプ・オルガノン | Ｔｒｐｖ１モジュレータとしての５−フェニル−イソオキサゾール−３−カルボキサミド誘導体 |
| WO2016026078A1 (en) | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
| WO2016205418A1 (en) | 2015-06-15 | 2016-12-22 | Asana Biosciences, Llc | Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer |
| WO2017080980A1 (en) * | 2015-11-09 | 2017-05-18 | Astrazeneca Ab | Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer |
-
2019
- 2019-06-06 EP EP19815477.5A patent/EP3805217A4/en not_active Withdrawn
- 2019-06-06 AU AU2019280356A patent/AU2019280356B2/en not_active Expired - Fee Related
- 2019-06-06 TW TW108119658A patent/TW202016102A/zh unknown
- 2019-06-06 JP JP2020568258A patent/JP2021525783A/ja active Pending
- 2019-06-06 SG SG11202012241RA patent/SG11202012241RA/en unknown
- 2019-06-06 KR KR1020217000434A patent/KR20210018915A/ko not_active Ceased
- 2019-06-06 CN CN201980031574.6A patent/CN112204024B/zh active Active
- 2019-06-06 US US16/973,335 patent/US11466013B2/en active Active
- 2019-06-06 WO PCT/CN2019/090221 patent/WO2019233457A1/zh not_active Ceased
- 2019-06-06 CA CA3103055A patent/CA3103055A1/en active Pending
-
2020
- 2020-12-08 IL IL279276A patent/IL279276A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021525783A5 (https=) | ||
| CN112204027A (zh) | Erk 抑制剂及其应用 | |
| JPWO2019233457A5 (https=) | ||
| JP2024532735A (ja) | 複素環式化合物及び使用方法 | |
| WO2021149817A1 (en) | Enhancement of anti-tumor activity of SHP2 inhibitor pyrimidinone in combination with novel cancer medicines in cancers | |
| CN117651700A (zh) | 2-氨基苯并噻唑化合物及使用方法 | |
| JP2024532733A (ja) | 複素環式化合物及び使用方法 | |
| RU2019115115A (ru) | Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7 | |
| RU2473549C2 (ru) | Пиримидиновые соединения, композиции и способы применения | |
| AU2023222076A1 (en) | Quinazoline compounds and use thereof as inhibtors of mutant kras proteins | |
| JP2013534902A5 (https=) | ||
| JP2025533831A (ja) | Ｋｒａｓ ｇ１２ｃ変異タンパク質のテザー型複素環式阻害剤及びその使用 | |
| RU2019120986A (ru) | Фармацевтическая комбинация, содержащая ингибитор alk и ингибитор shp2 | |
| TW202233629A (zh) | 雜環螺環化合物及使用方法 | |
| JP2011516558A5 (https=) | ||
| JP2019535664A5 (https=) | ||
| AU2021370660A1 (en) | Heterocyclic spiro compounds and methods of use | |
| JP2016537384A5 (https=) | ||
| JP2011500774A5 (https=) | ||
| JP2015511245A5 (https=) | ||
| JP2017503867A5 (https=) | ||
| JPWO2023018810A5 (https=) | ||
| JP2021521165A5 (https=) | ||
| RU2017141077A (ru) | Ингибитор некоторых протеинкиназ | |
| JPWO2022173033A5 (https=) |